RT Journal Article
T1 Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024.
A1 Rivera-Izquierdo, Mario
A1 Morales-Portillo, Arturo
A1 Guerrero-Fernández de Alba, Inmaculada
A1 Fernández-Martínez, Nicolás Francisco
A1 Schoenenberger-Arnaiz, Joan Antoni
A1 Barranco-Quintana, José Luis
A1 Valero-Ubierna, Carmen
K1 Biologic therapy
K1 biologics
K1 immunosuppression
K1 mAbs
K1 nirsevimab
K1 vaccine
K1 vaccine schedule
AB Introduction: Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.Areas covered: Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.Expert opinion: Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, which are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.
PB Taylor & Francis
SN 1476-0584
YR 2024
FD 2024-09-23
LK https://hdl.handle.net/10668/24290
UL https://hdl.handle.net/10668/24290
LA en
NO Rivera-Izquierdo M, Morales-Portillo A, Guerrero-Fernández de Alba I, Fernández-Martínez NF, Schoenenberger-Arnaiz JA, Barranco-Quintana JL, et al. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024. Expert Rev Vaccines. 2024 Jan-Dec;23(1):887-910.
DS RISalud
RD Apr 7, 2025